NEW YORK ─ Point-of-care diagnostics company PixCell Medical on Monday announced it has signed an exclusive distribution agreement with Gamidor Diagnostics to distribute PixCell's hematology analyzer, called HemoScreen, in Israel.
Gamidor provides systems, reagents, and services to clinical laboratories, hospitals, and academic research institutions in Israel.
HemoScreen is a US Food and Drug Administration-cleared and CE-marked five-part differential complete blood count, or CBC, analyzer for point-of-care use. The analyzer provides results with the accuracy of laboratory-based tests within five minutes, removing the need for specially trained lab technicians to operate the instrument, PixCell said.
Israel "is lagging in the implementation of point-of-care diagnostics, with CBC testing — the most common blood test — still exclusively conducted by professional technicians in centralized laboratories, an expensive, resource-heavy, and slow process that delays treatment," Avishay Bransky, cofounder and CEO of PixCell Medical, said in a statement.
In May, South Korean semiconductor firm Soulbrain Holdings announced it had acquired all of the controlling shares of PixCell and invested more than $40 million in the company.